Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: High-dose corticosteroids appear to play an important role in the management of highly pretreated relapsed/refractory CLL including patients with massive lymphadenopathy. Myelosuppression is usually limited but infectious toxicity, including increased risk of invasive fungal infections, represents the most dreaded side effects. This therapeutic approach should be further tested within large prospective trials, to optimize efficacy and safety.
|
Authors | Lukáš Smolej |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 21
Issue 7
Pg. 1009-17
(Jul 2012)
ISSN: 1744-7658 [Electronic] England |
PMID | 22616646
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Genes, p53
(genetics)
- Glucocorticoids
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, genetics)
- Mutation
- Treatment Outcome
|